Success Metrics

Clinical Success Rate
90.5%

Based on 95 completed trials

Completion Rate
90%(95/105)
Active Trials
8(5%)
Results Posted
53%(50 trials)
Terminated
10(7%)

Phase Distribution

Ph phase_4
36
24%
Ph early_phase_1
5
3%
Ph phase_3
27
18%
Ph phase_1
13
9%
Ph not_applicable
32
21%
Ph phase_2
26
17%

Phase Distribution

18

Early Stage

26

Mid Stage

63

Late Stage

Phase Distribution139 total trials
Early Phase 1First-in-human
5(3.6%)
Phase 1Safety & dosage
13(9.4%)
Phase 2Efficacy & side effects
26(18.7%)
Phase 3Large-scale testing
27(19.4%)
Phase 4Post-market surveillance
36(25.9%)
N/ANon-phased studies
32(23.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.6%

95 of 111 finished

Non-Completion Rate

14.4%

16 ended early

Currently Active

8

trials recruiting

Total Trials

149

all time

Status Distribution
Active(14)
Completed(95)
Terminated(16)
Other(24)

Detailed Status

Completed95
unknown23
Terminated10
Recruiting8
Not yet recruiting6
Withdrawn6

Development Timeline

Analytics

Development Status

Total Trials
149
Active
8
Success Rate
90.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 15 (3.6%)
Phase 113 (9.4%)
Phase 226 (18.7%)
Phase 327 (19.4%)
Phase 436 (25.9%)
N/A32 (23.0%)

Trials by Status

terminated107%
not_yet_recruiting64%
completed9564%
recruiting85%
suspended11%
unknown2315%
withdrawn64%

Recent Activity

Clinical Trials (149)

Showing 20 of 149 trialsScroll for more
NCT07372495Not Applicable

Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix

Recruiting
NCT06851754Phase 3

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Recruiting
NCT07508657Phase 4

Progesterone Supplementation After Letrozole-stimulated Insemination

Not Yet Recruiting
NCT04675788Phase 4

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Completed
NCT07425990Not Applicable

FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles

Not Yet Recruiting
NCT04499131Phase 4

Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters

Completed
NCT06807580Phase 2

Progesterone in Gender Affirming Hormone Therapy Study

Recruiting
NCT00001481Phase 2

The Role of Hormones in Postpartum Mood Disorders

Completed
NCT05704036Phase 4

Estrogen Supplementation and Bone Health in Women With CF

Recruiting
NCT06610305Phase 4

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Recruiting
NCT07162961Phase 3

Nintedanib for Improving Reproductive Outcomes in Adenomyosis

Not Yet Recruiting
NCT06668896Phase 1

Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert

Not Yet Recruiting
NCT03834883Phase 4

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Completed
NCT06631547Phase 1

Effect of Progesterone Administration on Severely Head Injured Patients

Not Yet Recruiting
NCT06928844Not Applicable

Role of Low Dose Injectable Progesterone in Triggering Ovulation

Recruiting
NCT03018366Phase 2

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

Completed
NCT06812559

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

Completed
NCT05903820Phase 4

Rhythmic Estradiol and Bone Health

Completed
NCT05286554Phase 4

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

Completed
NCT04209543Phase 3

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
149